Regular ArticleMechanisms of Lower Maintenance Dose of Tacrolimus in Obese Patients
References (47)
- et al.
Human P-glycoprotein transports cyclosporin A and FK506
J. Biol. Chem.
(1993) - et al.
Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes
Biochem. Pharmacol.
(1994) Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery
Adv. DrugDeliv. Rev.
(1997)- et al.
Influence of long- term enteral nutrition on pharmacokinetics of digoxin in rats
Drug Metab. Pharmacokinet.
(2013) - et al.
Effects of obesity induced by high-fat diet on the pharmacokinetics of cyclosporine A in rats
Biomed. Prev. Nutr.
(2011) - et al.
High initial blood levels of tacrolimus in overweight renal transplant recipients
Transplant. Proc.
(2005) - et al.
Validation of methods to study the distribution and protein binding of tacrolimus in human blood
J. Pharmacol. Toxicol. Methods
(2001) Increased red cell count in diabetes and pre-diabetes
Diabetes Res. Clin. Pract.
(2010)- et al.
Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats
J. Pharm. Sci.
(2002) - et al.
Regulation of the nitric oxide system in human adipose tissue
J. Lipid Res.
(2004)
Diet- induced weight loss reduces colorectal inflammation: implications for colorectal carcinogenesis
Am. J. Clin. Nutr.
(2011)
Inducible nitric oxide synthase-mediated decrease of intestinal P-glycoprotein expression under streptozotocin-induced diabetic conditions
Life Sci.
(2010)
Effect of tumor necrosis factor-alpha and interferon-gamma on intestinal P-glycoprotein expression, activity, and localization in Caco-2 cells
J. Pharm. Sci.
(2004)
Obesity and Overweight
Effects ofobesity on the cytochrome P450 enzyme system
Int. J. Clin. Pharmacol. Ther.
(1999)
Implications of obesity for drug therapy: limitations and challenges
Clin. Pharmacol. Ther.
(2011)
Pharmacokinetics of FK 506: preclinical and clinical studies
Transplant. Proc.
(1990)
506 Study Group: Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration
Transplant. Proc.
(1991)
Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy
Transplantation
(2002)
Effect ofintestinal P-glycoprotein on daily Tacrolimus trough level in a living donor small bowel recipient
Clin. Pharmacol. Ther.
(2000)
Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation
Clin. Pharmacol. Ther.
(2001)
Hepatic cytochrome P450 regulation in disease states
Curr. Drug Metab.
(2001)
Hepatic CYP3A expression is attenuated in obese mice fed a high-fat diet
Pharm. Res.
(2006)
Cited by (20)
Fructose-induced metabolic syndrome decreases protein expression and activity of intestinal P-glycoprotein
2015, NutritionCitation Excerpt :At this stage of our study, we cannot assess the mechanisms involved in the decreased expression of intestinal P-gp protein in fructose-drinking rats. However, it has been proposed that the lower expression of intestinal P-gp in obese Zucker rats could be associated with the enhanced production of proinflammatory factors, such as tumor necrosis factor (TNF)-α, interleukin-6, and iNOS [13]. Moreover, it was reported that TNF-α reduces the expression and activity of P-gp in Caco-2 cells [38].
Obesity-related genomic instability and altered xenobiotic metabolism: possible consequences for cancer risk and chemotherapy
2022, Expert Reviews in Molecular MedicineIndividualized dosing algorithms for tacrolimus in kidney transplant recipients: current status and unmet needs
2023, Expert Opinion on Drug Metabolism and ToxicologyA pharmacist-led intervention to improve kidney transplant recipient outcomes and identify patients at risk of highly variable trough tacrolimus levels: a cohort study
2023, European Journal of Hospital PharmacyBody composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients
2022, European Journal of Clinical Pharmacology
This work was supported in part by JSPS KAKENHI Grants No. 24790149 and No. 23590173.
Copyright © 2014 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.